1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
    Journal Article

    Ruan, J.; Moskowitz, A.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Kotlov, N.; Nos, G.; Sorokina, M.; Maksimov, V.; Sboner, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: Opportunity and challenge
    Journal Article

    Keane, F.; Bajwa, R.; Selenica, P.; Park, W.; Roehrl, M. H.; Reis-Filho, J. S.; Mandelker, D.; O’Reilly, E. M.
    npj Precision Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: Final analysis of KEYNOTE-164
    Journal Article

    Le, D. T.; Diaz, L. A. Jr; Kim, T. W.; Van Cutsem, E.; Geva, R.; Jäger, D.; Hara, H.; Burge, M.; O'Neil, B. H.; Kavan, P.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
    Journal Article

    Issa, G. C.; Aldoss, I.; DiPersio, J.; Cuglievan, B.; Stone, R.; Arellano, M.; Thirman, M. J.; Patel, M. R.; Dickens, D. S.; Shenoy, S.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
    Conference Paper

    Lengel, H. B.; Zheng, J.; Tan, K. S.; Liu, C. C.; Park, B. J.; Rocco, G.; Adusumilli, P. S.; Molena, D.; Yu, H. A.; Riely, G. J.; more...
    Mosby Elsevier (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Autio, K. A.; Higano, C. S.; Nordquist, L.; Appleman, L. J.; Zhang, T.; Zhu, X. H.; Babiker, H.; Vogelzang, N. J.; Prasad, S. M.; Schweizer, M. T.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • The herbal medicine Suanzaoren (Ziziphi Spinosae Semen) for sleep quality improvements: A systematic review and meta-analysis
    Review

    Yang, M.; Wang, H.; Zhang, Y. L.; Zhang, F.; Li, X.; Kim, S. D.; Chen, Y.; Chen, J.; Chimonas, S.; Korenstein, D.; more...
    Integrative Cancer Therapies (2023)

    Fulltext@MSK | Save